What to do if a patient, who is immunocompetent, received the first dose of Shingrix (recombinant zoster vaccine) but missed the second dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Missed Second Dose of Shingrix in Immunocompetent Patient

For an immunocompetent patient who received the first Shingrix dose on 10/07/2024 and missed the second dose, administer the second dose as soon as possible without restarting the series—there is no maximum interval between doses. 1

Key Management Principles

No Need to Restart the Series

  • The vaccine series does not need to be restarted regardless of how much time has elapsed since the first dose. 1
  • Simply administer the second dose at the next available opportunity to complete the two-dose series 1
  • The minimum interval between doses is 4 weeks; if the second dose is given earlier than this, it should be repeated 1

Optimal Timing Considerations

  • The recommended interval is 2-6 months after the first dose for immunocompetent adults 1
  • Real-world data shows that delayed second doses (administered beyond 6 months) do not impair vaccine effectiveness 2
  • Studies demonstrate that second doses received at ≥180 days maintain similar effectiveness to those given within the recommended window 2

Expected Effectiveness

  • Two-dose vaccine effectiveness is 70.1% in real-world settings, significantly higher than the 56.9% effectiveness of a single dose 2
  • Completing the two-dose series is critical for optimal protection—single-dose protection is substantially inferior 2
  • Real-world effectiveness of 50% has been documented even in immunocompromised populations with inflammatory arthritis 3

Series Completion Rates

  • Among patients who received a first dose, approximately 70% completed the series within 6 months and 80% within 12 months 4
  • Of those who received a second dose, 83.8% received it within the recommended 2-6 month window 3

Clinical Pitfalls to Avoid

  • Do not restart the series—this wastes vaccine and delays protection 1
  • Do not wait indefinitely; administer the second dose promptly once the patient presents 2
  • Do not assume single-dose protection is adequate; emphasize the importance of series completion 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.